E

Fishing for Gems from the Poster Halls Part 1

Bispecifics come and bispecifics go as companies seek to find a balance

September 29, 2022
E

Reflections on ESMO22

What really stood out from the oral presentations at ESMO this year?

September 16, 2022
E

Analysis of the CodeBreak 200 trial in lung cancer

An in-depth look at some of the issues impacting Amgen's pivotal trial and what it means for their competitors

September 14, 2022
E

Sorting out confusion, confliction, and confounding results in clear cell RCC

How do we help more early stage ccRCC patients live long and prosper?

September 12, 2022
E

Time to change lines in breast cancer?

Round up ad discussion of key breast cancer trials in HR+/HER2- disease

September 11, 2022
E

Making your mind up

Are all PARP inhibitors the same?

September 10, 2022
E

ESMO22 Preview on Targeted Therapies in Developmental Therapeutics

New developments in early stage targeted therapy agents

September 6, 2022
E

ESMO22 Developmental Therapeutics Preview on Immunotherapies

In our latest ESMO conference preview it’s time to pick some early stage immunotherapy highlights…

August 31, 2022
E

New controversies in GI malignancies

What to watch out for in colorectal cancer, cholangiocarcinoma and hepatocellular carcinoma

August 24, 2022
E

ESMO22 Preview 1 – what to watch out for in breast cancer

Review of some of the key trials in breast cancer being showcased in Paris next month

August 22, 2022